Subtopic Deep Dive
Plasma Cancer Therapy Mechanisms
Research Guide
What is Plasma Cancer Therapy Mechanisms?
Plasma Cancer Therapy Mechanisms study the biological processes by which cold atmospheric plasma induces tumor cell death through reactive oxygen and nitrogen species, immunogenic cell death, and vascular disruption.
Cold atmospheric plasma (CAP) generates reactive species that selectively target cancer cells while sparing normal cells (Keidar et al., 2011, 742 citations). Key mechanisms include DNA damage, apoptosis induction, and immune modulation via plasma-activated media (Utsumi et al., 2013, 403 citations). Over 10 papers from 2010-2019 detail preclinical efficacy against chemo-resistant cancers.
Why It Matters
CAP targets cancer hallmarks like metabolic dysregulation and immune evasion, showing synergy with checkpoint inhibitors in preclinical ovarian cancer models (Utsumi et al., 2013). Keidar et al. (2011) demonstrated selective apoptosis in tumor cells, enabling non-thermal treatment for inaccessible tumors. Yan et al. (2016, 514 citations) highlight CAP's potential to overcome chemotherapy resistance, improving outcomes in solid tumors via indirect plasma-activated medium delivery.
Key Research Challenges
Species Transport Modeling
Predicting reactive oxygen/nitrogen species diffusion from plasma to tumor sites remains imprecise due to complex gas-liquid interfaces (Lu et al., 2016, 1141 citations). In vivo transport differs from in vitro models, complicating dosimetry (Keidar et al., 2013, 490 citations).
Selectivity Mechanism Elucidation
Exact pathways for CAP's preferential cancer cell killing versus normal cells require deeper redox biology insights (Keidar et al., 2011, 742 citations). Variable tumor microenvironments challenge universal selectivity claims (Yan et al., 2016).
Clinical Translation Barriers
Preclinical success in chemo-resistant ovarian cancer (Utsumi et al., 2013) faces scalability issues for human trials due to device standardization. Long-term immunogenicity and combination therapy safety need validation (Hoffmann et al., 2013).
Essential Papers
Reactive species in non-equilibrium atmospheric-pressure plasmas: Generation, transport, and biological effects
Xinpei Lu, G V Naĭdis, Mounir Laroussi et al. · 2016 · Physics Reports · 1.1K citations
Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy
Michael Keidar, Ryan M. Walk, Alexey Shashurin et al. · 2011 · British Journal of Cancer · 742 citations
Cold atmospheric plasma, a novel promising anti-cancer treatment modality
Dayun Yan, Jonathan H. Sherman, Michael Keidar · 2016 · Oncotarget · 514 citations
Over the past decade, cold atmospheric plasma (CAP), a near room temperature ionized gas has shown its promising application in cancer therapy. Two CAP devices, namely dielectric barrier discharge ...
Cold atmospheric plasma in cancer therapy
Michael Keidar, Alexey Shashurin, Olga Volotskova et al. · 2013 · Physics of Plasmas · 490 citations
Recent progress in atmospheric plasmas has led to the creation of cold plasmas with ion temperature close to room temperature. This paper outlines recent progress in understanding of cold plasma ph...
Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo
Fumi Utsumi, Hiroaki Kajiyama, Kae Nakamura et al. · 2013 · PLoS ONE · 403 citations
We demonstrated that plasma-activated medium also had an anti-tumor effect on chemo-resistant cells in vitro and in vivo. Indirect plasma therapy is a promising treatment option for EOC and may con...
Cold Atmospheric Plasma: methods of production and application in dentistry and oncology
Clotilde Hoffmann, Carlos J Berganza, John H. Zhang · 2013 · Medical Gas Research · 390 citations
Plasma Medicine: Applications of Cold Atmospheric Pressure Plasma in Dermatology
Thoralf Bernhardt, Marie Semmler, Mirijam Schäfer et al. · 2019 · Oxidative Medicine and Cellular Longevity · 368 citations
The ability to produce cold plasma at atmospheric pressure conditions was the basis for the rapid growth of plasma-related application areas in biomedicine. Plasma comprises a multitude of active c...
Reading Guide
Foundational Papers
Start with Keidar et al. (2011, 742 citations) for CAP selectivity concept, then Keidar et al. (2013, 490 citations) for physics-biology links, and Utsumi et al. (2013, 403 citations) for indirect therapy validation.
Recent Advances
Study Lu et al. (2016, 1141 citations) for species mechanisms and Yan et al. (2016, 514 citations) for anti-cancer capacity advances.
Core Methods
Core techniques: dielectric barrier discharge, plasma jets, plasma-activated medium delivery targeting RONS-induced apoptosis and immune modulation (Keidar et al., 2013; Hoffmann et al., 2013).
How PapersFlow Helps You Research Plasma Cancer Therapy Mechanisms
Discover & Search
Research Agent uses citationGraph on Keidar et al. (2011, 742 citations) to map 490+ citing works on CAP selectivity, then exaSearch for 'plasma-activated medium ovarian cancer' to uncover Utsumi et al. (2013). findSimilarPapers expands to Yan et al. (2016) for immunogenic mechanisms.
Analyze & Verify
Analysis Agent applies readPaperContent to extract reactive species data from Lu et al. (2016), then runPythonAnalysis with NumPy/pandas to model transport kinetics from abstracts. verifyResponse (CoVe) with GRADE grading scores evidence strength for selectivity claims in Keidar et al. (2011), flagging low in vivo validation.
Synthesize & Write
Synthesis Agent detects gaps in vascular disruption studies via contradiction flagging across Keidar et al. (2013) and Utsumi et al. (2013), then Writing Agent uses latexSyncCitations and latexCompile to generate mechanism review sections. exportMermaid visualizes RONS-induced apoptosis pathways from Lu et al. (2016).
Use Cases
"Analyze reactive species concentrations from plasma cancer papers with Python plotting."
Research Agent → searchPapers('plasma reactive species cancer') → Analysis Agent → readPaperContent(Lu et al. 2016) → runPythonAnalysis(pandas/matplotlib concentration curves) → researcher gets publication-ready species transport plots.
"Write LaTeX review on CAP selectivity mechanisms citing Keidar 2011."
Synthesis Agent → gap detection(Keidar et al. 2011 vs. Yan et al. 2016) → Writing Agent → latexEditText(intro section) → latexSyncCitations(10 papers) → latexCompile → researcher gets compiled PDF with synced bibliography.
"Find code for plasma dosimetry simulations in cancer therapy papers."
Research Agent → searchPapers('plasma cancer simulation code') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets verified simulation scripts linked to Keidar et al. (2013) methods.
Automated Workflows
Deep Research workflow scans 50+ CAP papers via searchPapers → citationGraph, producing structured reports on mechanisms with GRADE scores from Keidar et al. (2011). DeepScan's 7-step chain verifies selectivity claims: readPaperContent → runPythonAnalysis(dose-response) → CoVe on Utsumi et al. (2013). Theorizer generates hypotheses on RONS synergy with immunotherapy from Lu et al. (2016) abstracts.
Frequently Asked Questions
What defines plasma cancer therapy mechanisms?
Mechanisms involve CAP-generated reactive species inducing selective apoptosis, immunogenic cell death, and vascular effects in tumors (Keidar et al., 2011).
What are primary methods in plasma cancer therapy?
Dielectric barrier discharge and plasma jets deliver RONS via direct treatment or plasma-activated medium, tested in vitro/in vivo on ovarian cancer (Utsumi et al., 2013; Yan et al., 2016).
What are key papers on plasma cancer mechanisms?
Keidar et al. (2011, 742 citations) on selectivity; Lu et al. (2016, 1141 citations) on species generation; Utsumi et al. (2013, 403 citations) on chemo-resistant efficacy.
What open problems exist in plasma cancer therapy?
Challenges include precise species dosimetry in vivo, selectivity pathway details, and clinical scalability beyond preclinical models (Lu et al., 2016; Keidar et al., 2013).
Research Plasma Applications and Diagnostics with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Plasma Cancer Therapy Mechanisms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers